Drugs News and Research

RSS

New method for measuring genetic variability may help identify patients with aggressive cancers

A new method for measuring genetic variability within a tumor might one day help doctors identify patients with aggressive cancers that are more likely to resist therapy, according to a study led by researchers now at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

17 Apr 2015

Electronic micropump combined with anticonvulsant drug may treat brain diseases

Many potentially efficient drugs have been created to treat neurological disorders, but they cannot be used in practice. Typically, for a condition such as epilepsy, it is essential to act at exactly the right time and place in the brain.

16 Apr 2015

ChemRar, Lancet partner to develop and commercialize new medicines in Russia

ChemRar High Tech Center, the Russian pharmaceutical investment and R&D group, and Lancet, Russian Distribution Company, have announced collaboration for research, development and commercialization of new medicines in Russia with the intention to stimulate the innovative development of the Russian pharmaceutical industry.

16 Apr 2015

Study paves way for greater understanding of Attention Deficit Hyperactivity Disorder

Researchers at the Angiocardioneurology Department of the Neuromed Scientific Institute for Research, Hospitalisation and Health Care of Pozzilli (Italy), have found, in animal models, that the absence of a certain enzyme causes a syndrome resembling the Attention Deficit Hyperactivity Disorder (ADHD).

16 Apr 2015

Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

Nearly anyone touched by ovarian cancer will tell you: it's devastating. It's bad enough that cancer in almost 80 percent of patients reaches advanced stages before diagnosis, and that most patients are expected to die within five years. But just as painfully, roughly one quarter of women diagnosed have no warning that they are resistant to platinum-based chemotherapy, the main line of defense, nor that they will likely have 18 months to live.

16 Apr 2015

UAB research findings may lead to better treatment for women with HER2+ breast cancer

There are five subtypes of breast cancer, and they are distinct diseases with vastly different biologies that drastically alter their progression and responses to treatment. Understanding those differences is the starting point to a more effective, personalized treatment of breast cancer, which strikes more than 230,000 women in the U.S. each year.

16 Apr 2015

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma. The trial, for which Yale is a lead site, will enroll patients lacking a particular genetic mutation for whom immune therapy did not work or was not an option.

16 Apr 2015

Research findings could bolster efforts to develop next gen of anti-viral treatments

A newly developed spectroscopy method is helping to clarify the poorly understood molecular process by which an anti-HIV drug induces lethal mutations in the virus's genetic material.

16 Apr 2015

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Effimune announced today that it had received the authorization from the Belgian regulatory authority, the FAMHP (Federal Agency for Medicines and Health Products) for a Phase I clinical trial of FR104, its drug candidate for controlling the regulation of the immune system...

16 Apr 2015

Itraconazole drug shows potential in cancer treatment

A common anti-fungal treatment has joined the ranks of drugs that may be suitable for use in treating cancer, according to research from the Repurposing Drugs in Oncology (ReDO) project published in ecancermedicalscience.

16 Apr 2015

New research links megalin protein with malignant melanomas

Today it is not possible to predict spreading from malignant melanomas. Melanoma metastases are furthermore extremely difficult to eliminate as traditional treatment such as chemotherapy and radiotherapy is mostly ineffective. Only ten per cent of the patients survive once they reach an advanced stage with distant metastases.

16 Apr 2015

Novel findings may hold promise for children, adults with mitochondrial disorders

Rooted in malfunctions in the tiny power plants that energize our cells, mitochondrial disorders are notoriously complex and variable, with few effective treatments. Now, novel findings in microscopic worms may hold great promise for children and adults with mitochondrial disorders

16 Apr 2015

New set of molecules could carry medicines into cells

Just as a scientist dressed in a lab coat and goggles might get stuck behind the velvet rope at a trendy bar, many otherwise good drugs can't get inside cells if they don't look the part. In a report published this week in ACS Central Science, researchers report a new set of molecules that could ferry medicines into cells by taking on the right charge and shape, easily sliding past lipid membranes.

16 Apr 2015

Oxycodone-related deaths drop 25% after implementation of Prescription Drug Monitoring Program

Oxycodone-related deaths dropped 25 percent after Florida implemented its Prescription Drug Monitoring Program in late 2011 as part of its response to the state's prescription drug abuse epidemic, according to a team of UF Health researchers. The drop in fatalities could stem from the number of health care providers who used the program's database to monitor controlled substance prescriptions.

16 Apr 2015

NIH-supported clinical trial to test statin use in patients with HIV-related cardiovascular disease

Researchers have begun enrolling participants in a multicenter international clinical trial to test whether statin administration can reduce the risk for major adverse cardiovascular events, such as heart attacks, strokes, and heart disease, in people with HIV infection. The trial is supported by the National Institutes of Health's National Heart, Lung, and Blood Institute and National Institute of Allergy and Infectious Diseases.

16 Apr 2015

Changes in JAK/STAT3 cell signaling pathway drive ALK-negative ALCL

The first-ever systematic study of the genomes of patients with ALK-negative anaplastic large cell lymphoma (ALCL), a particularly aggressive form of non-Hodgkin's lymphoma, shows that many cases of the disease are driven by alterations in the JAK/STAT3 cell signaling pathway.

15 Apr 2015

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.

15 Apr 2015

WHO issues public statement calling for transparency in medical research

WHO today issued a public statement calling for the disclosure of results from clinical trials for medical products, whatever the result.The move aims to ensure that decisions related to the safety and efficacy of vaccines, drugs and medical devices for use by populations are supported by the best available evidence.

15 Apr 2015

Clyde Biosciences announces £2 million ‘Series A’ investment

Clyde Biosciences Ltd. has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund.

15 Apr 2015

Cantab Connect CTIS-Abuse Liability product exceeds $1.5m sales in first 9 months

Cambridge Cognition Holdings plc,the developer of cognitive assessment software, announces that sales of Cantab Connect CTIS-Abuse Liability have exceeded £1m in its first 9 months from launch.

15 Apr 2015

Drugs News and Research

New method for measuring genetic variability may help identify patients with aggressive cancers

Electronic micropump combined with anticonvulsant drug may treat brain diseases

ChemRar, Lancet partner to develop and commercialize new medicines in Russia

Study paves way for greater understanding of Attention Deficit Hyperactivity Disorder

Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

UAB research findings may lead to better treatment for women with HER2+ breast cancer

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Research findings could bolster efforts to develop next gen of anti-viral treatments

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Itraconazole drug shows potential in cancer treatment

New research links megalin protein with malignant melanomas

Novel findings may hold promise for children, adults with mitochondrial disorders

New set of molecules could carry medicines into cells

Oxycodone-related deaths drop 25% after implementation of Prescription Drug Monitoring Program

NIH-supported clinical trial to test statin use in patients with HIV-related cardiovascular disease

Changes in JAK/STAT3 cell signaling pathway drive ALK-negative ALCL

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

WHO issues public statement calling for transparency in medical research

Clyde Biosciences announces £2 million ‘Series A’ investment

Cantab Connect CTIS-Abuse Liability product exceeds $1.5m sales in first 9 months

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News